RMD logo

RESMED INC

RMDNYSE
πŸ† #414 by market capEarnings Oct 22US Equity
$221.49β–Ό $0.60 (βˆ’0.27%)
Live
πŸ””
Track RMD
Get earnings, price moves & breaking news on Telegram
Track
24hβ–Ό 0.3%
7dβ–Ό 0.2%
14dβ–Ό 3.5%
30dβ–Ό 7.8%
ytdβ–Ό 8.0%
1yβ–Ό 18.3%
🏦Market Cap
$32.13B
Mid Cap
πŸ“ˆRevenue Growth (YoY)
+9.8%
Slowing
πŸ“ŠGross Margin
61.1%
High
πŸ’΅FCF Margin
28.8%
Strong
βš–οΈP/S Ratio
5.7x
Fair
Otter Score
72
Fair

Trading Snapshot

Day Range
$219.20 – $225.76
52-Week Range
$180.27 – $284.87
Volume
$1.72B
Avg Volume
$2.12B
Shares Outstanding
145.1M
Next Earnings
Dec 13, 2026

Fundamentals Snapshot

Annual Revenue
$5.65B
Last Q Revenue
$1.46B
P/E Ratio
21.0
P/S Ratio
5.7x
EPS (TTM)
$10.44
Dividend Yield
1.09%
Dilution (1yr)
βˆ’1.4%

Why Investors Own RMD

  • βœ“High-growth profile β€” revenue up +32.9% YoY with expanding US Equity exposure.
  • βœ“Healthy economics β€” 49% gross margin and 6% free-cash-flow margin.
  • βœ“New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

RMD logo

RESMED INC

RMD
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$5.7Bβ–² +9.9% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
61.2%β–² +3.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
$1.9Bβ–² +12.3% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$1.6Bβ–Ό βˆ’0.7% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
145.0Mβ–Ό βˆ’1.4% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$643Mβ–² +$228M YoY
StockOtter Β· stockotter.space

About RESMED INC

ResMed Inc. is a leading global medical technology enterprise engaged in the creation, production, distribution, and marketing of healthcare devices and connected digital solutions. The company operates through two primary segments: Sleep and Respiratory Care, and Software as a Service. Its extensive product range addresses a variety of respiratory disorders, encompassing advanced medical and consumer technologies, ventilation devices, diagnostic equipment, mask systems for both clinical and personal use, headgear, and related accessories, alongside dental devices. ResMed also provides sophisticated cloud-based informatics to enhance patient management and operational efficiency. Notable software offerings in its respiratory portfolio include AirView, for remote device monitoring and setting adjustments; myAir, a personalized application designed to support sleep apnea patients with education and troubleshooting for better engagement and adherence; and U-Sleep, a compliance tracking platform for home medical equipment providers. Complementing these are connectivity modules and Propeller solutions. Furthermore, ResMed offers a robust suite of out-of-hospital software. This includes Brightree, a business management platform for various home care service providers (e.g., HME, pharmacy, infusion, orthotics, prosthetics); MatrixCare, providing care management for senior living, skilled nursing, and hospice organizations; and HEALTHCAREfirst, which supplies electronic health records, billing, coding services, and analytics for home health and hospice agencies. ResMed distributes its offerings primarily to sleep clinics, home healthcare dealers, and hospitals via a global network of distributors and a direct sales force, serving approximately 140 countries. Founded in 1989, the company's headquarters are located in San Diego, California.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Fair
72/100

Analyst Ratings

β“˜
Consensus
Buy
27 analysts
Strong Buy4
Buy9
Hold12
Sell1
Strong Sell1
Ratings as of Sep 2026

Latest News & Updates

Defense WorldΒ·7d ago

ResMed Targets 12%-14% EPS Growth as GLP-1 Patients Lift Sleep Therapy Demand

ResMed (NYSE: RMD) outlined its growth outlook, margin strategy and portfolio plans during a Morgan Stanley discussion, with executives emphasizing demand generation, patient adherence and ongoing product innovation in s

Defense WorldΒ·12d ago

Engineers Gate Manager LP Has $1.58 Million Stake in ResMed Inc. $RMD

Engineers Gate Manager LP raised its stake in ResMed Inc. (NYSE: RMD) by 77.8% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 8,127 sh

BarronsΒ·14d ago

Sleep Device Maker ResMed Gets an Upgrade. Analysts See a Lot to Like.

Setbacks for competitors have positioned ResMed to capture more market share.

Seeking AlphaΒ·14d ago

Wall Street Lunch: AI Regulation Hopes Fade After Trump Calls AI Concerns A 'Hoax'

AI regulation odds have sharply declined after Trump dismissed AI takeover concerns during a public call with Nvidia (NVDA) CEO Jensen Huang. ResMed (RMD) was upgraded to Outperform by RBC Capital Markets, with a price t

Seeking AlphaΒ·14d ago

ResMed Inc. (RMD) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

ResMed Inc. (RMD) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Zacks Investment ResearchΒ·14d ago

Is This the Right Time to Retain Resmed Stock in Your Portfolio?

RMD's software portfolio optimization, mask innovation and solid financial health support growth, though macro pressures and competition pose risks.